lentiviruses encoding shRNAs against CycE1 or p53 were used as controls of reduced or increased reprogramming efficiency. In (b) retroviruses encoding p16 or the pair CDK4/CycD1 were used as controls of reduced or increased reprogramming efficiency, respectively. For (a, b), 10,000 infected cells were plated under all the conditions. For (c), a total of 12,000 infected cells were plated under all conditions. Two independent experiments with two biological replicates were carried out. All error bars depict the standard deviation. This gene encodes a member of the CD1 family of transmembrane glycoproteins, which are structurally related to the major histocompatibility complex (MHC) proteins and form heterodimers with beta-2-microglobulin. D51E DAMAGING NO NRP1 (Neuropilin 1) NRP1 is a membrane-bound coreceptor to a tyrosine kinase receptor for both vascular endothelial growth factor (VEGF; MIM 192240) and semaphorin (see SEMA3A; MIM 603961) family members. G497D DAMAGING NO NEK11 (NIMA (never in mitosis gene a)-related kinase 11)
Supplementary
The encoded protein localizes to the nucleoli, and may function with NEK2A in the S-phase checkpoint. The encoded protein appears to play roles in DNA replication and response to genotoxic stress. R358M TOLERATED YES CTSL1 (cathepsin L1)
The protein encoded by this gene is a lysosomal cysteine proteinase that plays a major role in intracellular protein catabolism. V239I DAMAGING NO ASB3 (ankyrin repeat and SOCS box containing 3)
The protein encoded by this gene is a member of the ankyrin repeat and SOCS box-containing (ASB) family of proteins. They contain ankyrin repeat sequence and SOCS box domain. The SOCS box serves to couple suppressor of cytokine signalling (SOCS) proteins and their binding partners with the elongin B and C complex, possibly targeting them for degradation. G79S TOLERATED YES ZNF16 (zinc finger protein 16)
The protein encoded by this gene contains a C2H2 type of zinc finger, and thus may function as a transcription factor. Z59I DAMAGING NO Supplementary Table 3 
